ResearchMoz presents professional and in-depth study of "Biosimilar Monoclonal Antibodies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025".
Biosimilar monoclonal antibodies can be defined as biological molecules derived from living cells or organisms. These are large complex molecules. Biosimilars are developed after the expiry of patent of approved recombinant drugs, and are also known as biologics. These biologics display a certain level of variability which can be attributed to the variations in the biological expression system of the recombinant and the manufacturing process. Biosimilars are regulated by the various governing bodies in different countries. In the U.S., the FDA regulates the release of these biosimilars, which are required to undergo pharmacovigilance regulations as its reference approved monoclonal antibody. In Europe, biosimilars are approved by the European Medicines Agency (EMEA). Manufacturers of biosimilars are required to submit risk management plan in addition to the marketing application.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1380384
Increase in patent expiries of blockbuster monoclonal antibodies has led to a rise in interest among pharmaceutical companies to develop biosimilars. This is projected to drive the market during the forecast period. Focus on research and development contributing to innovative product pipeline and expanding health care infrastructure fuel the growth of the biosimilar monoclonal antibodies market. Additionally, increasing demand for cost effective treatment among patients boosts the growth of the market. Furthermore, launch of biosimilars owing to the patent expiries of Johnson & Johnson’s Remicade, Roche’s Herceptin, and Abbott’s Humira is one of the major factors propelling the market. However, stringent regulations related to product approvals and cost structure associated with the manufacturing process are likely to hamper market growth during the forecast period. Furthermore, lack of clarity related to the regulations concerning the development of biosimilar monoclonal antibodies in various emerging markets is expected to act as a restraint of the market.
The global biosimilar monoclonal antibodies market can be segmented based on indication, molecule, distribution channel, and region. In terms of indication, the market can be categorized into autoimmune diseases, oncology, hematology, gastrointestinal diseases, and others. Based on molecule, the biosimilar monoclonal antibodies market can be classified into bevacizumab, trastuzumab, infliximab, rituximab, abciximab, and adalimumab. The rituximab and infliximab segments are anticipated to dominate the market during the forecast period. Oncology was the dominant segment in 2016 and the trend is anticipated to continue in the next few years. In terms of distribution channel, the market can be divided into hospital pharmacies, retail pharmacies, specialty pharmacies, and others. The retail pharmacies and others segments, which includes online pharmacies, are anticipated to record substantial growth during the forecast period.
Geographically, the global biosimilar monoclonal antibodies market can be segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the highest share of the global market in terms of revenue in 2016 and the trend is anticipated to continue during the forecast period. Strong growth in the region can be attributed to increase in product approvals, well-established health care infrastructure, and favorable reimbursement scenario. Europe is expected to be the second leading market for biosimilar monoclonal antibodies. However, the sluggish economy in the region is likely to negatively impact the growth of the market. The market in Asia Pacific is anticipated to record a significantly high CAGR owing to factors such as increasing patient population, growing government focus on enhancing health care facilities, and increase in product approvals in Japan.
Make An Enquiry About TOC with tables & Figures @ https://www.researchmoz.us/enquiry.php?type=E&repid=1380384
Leading players operating in the global biosimilar monoclonal antibodies market are Biocon Limited, Allergan plc, Accord Healthcare Ltd., Boehringer Ingelheim GmbH, 3SBio, Inc., Novartis AG, Amgen, Inc., Alvartis Pharma, Pfizer, Inc., Celltrion, Alfred E. Tiefenbacher (GmbH & Co. KG), Hospira, and Dr. Reddy's Laboratories, among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Browse Report @ https://www.researchmoz.us/biosimilar-monoclonal-antibodies-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html
Highlights of the report:
A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
Biosimilar monoclonal antibodies can be defined as biological molecules derived from living cells or organisms. These are large complex molecules. Biosimilars are developed after the expiry of patent of approved recombinant drugs, and are also known as biologics. These biologics display a certain level of variability which can be attributed to the variations in the biological expression system of the recombinant and the manufacturing process. Biosimilars are regulated by the various governing bodies in different countries. In the U.S., the FDA regulates the release of these biosimilars, which are required to undergo pharmacovigilance regulations as its reference approved monoclonal antibody. In Europe, biosimilars are approved by the European Medicines Agency (EMEA). Manufacturers of biosimilars are required to submit risk management plan in addition to the marketing application.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1380384
Increase in patent expiries of blockbuster monoclonal antibodies has led to a rise in interest among pharmaceutical companies to develop biosimilars. This is projected to drive the market during the forecast period. Focus on research and development contributing to innovative product pipeline and expanding health care infrastructure fuel the growth of the biosimilar monoclonal antibodies market. Additionally, increasing demand for cost effective treatment among patients boosts the growth of the market. Furthermore, launch of biosimilars owing to the patent expiries of Johnson & Johnson’s Remicade, Roche’s Herceptin, and Abbott’s Humira is one of the major factors propelling the market. However, stringent regulations related to product approvals and cost structure associated with the manufacturing process are likely to hamper market growth during the forecast period. Furthermore, lack of clarity related to the regulations concerning the development of biosimilar monoclonal antibodies in various emerging markets is expected to act as a restraint of the market.
The global biosimilar monoclonal antibodies market can be segmented based on indication, molecule, distribution channel, and region. In terms of indication, the market can be categorized into autoimmune diseases, oncology, hematology, gastrointestinal diseases, and others. Based on molecule, the biosimilar monoclonal antibodies market can be classified into bevacizumab, trastuzumab, infliximab, rituximab, abciximab, and adalimumab. The rituximab and infliximab segments are anticipated to dominate the market during the forecast period. Oncology was the dominant segment in 2016 and the trend is anticipated to continue in the next few years. In terms of distribution channel, the market can be divided into hospital pharmacies, retail pharmacies, specialty pharmacies, and others. The retail pharmacies and others segments, which includes online pharmacies, are anticipated to record substantial growth during the forecast period.
Geographically, the global biosimilar monoclonal antibodies market can be segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the highest share of the global market in terms of revenue in 2016 and the trend is anticipated to continue during the forecast period. Strong growth in the region can be attributed to increase in product approvals, well-established health care infrastructure, and favorable reimbursement scenario. Europe is expected to be the second leading market for biosimilar monoclonal antibodies. However, the sluggish economy in the region is likely to negatively impact the growth of the market. The market in Asia Pacific is anticipated to record a significantly high CAGR owing to factors such as increasing patient population, growing government focus on enhancing health care facilities, and increase in product approvals in Japan.
Make An Enquiry About TOC with tables & Figures @ https://www.researchmoz.us/enquiry.php?type=E&repid=1380384
Leading players operating in the global biosimilar monoclonal antibodies market are Biocon Limited, Allergan plc, Accord Healthcare Ltd., Boehringer Ingelheim GmbH, 3SBio, Inc., Novartis AG, Amgen, Inc., Alvartis Pharma, Pfizer, Inc., Celltrion, Alfred E. Tiefenbacher (GmbH & Co. KG), Hospira, and Dr. Reddy's Laboratories, among others.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
Market segments and sub-segments
Market trends and dynamics
Supply and demand
Market size
Current trends/opportunities/challenges
Competitive landscape
Technological breakthroughs
Value chain and stakeholder analysis
The regional analysis covers:
North America (U.S. and Canada)
Latin America (Mexico, Brazil, Peru, Chile, and others)
Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
Eastern Europe (Poland and Russia)
Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Browse Report @ https://www.researchmoz.us/biosimilar-monoclonal-antibodies-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html
Highlights of the report:
A complete backdrop analysis, which includes an assessment of the parent market
Important changes in market dynamics
Market segmentation up to the second or third level
Historical, current, and projected size of the market from the standpoint of both value and volume
Reporting and evaluation of recent industry developments
Market shares and strategies of key players
Emerging niche segments and regional markets
An objective assessment of the trajectory of the market
Recommendations to companies for strengthening their foothold in the market
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
No comments:
Post a Comment